The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya
Kohler, Jessica
Arieta, Christina M.
Haanen, John B.
Demario, Mark
Gaynor, Richard
Abstract
Generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
The filed of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
The present disclosure relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject
Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
ex vivoex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.
Provided herein are methods of producing a plurality of T cells which has been ex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.
Provided herein are methods of producing a plurality of T cells which has been ex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present disclosure provides a therapy with vaccine compositions including multiepitopic polypeptides, recombinant nucleic acids encoding multiepitopic polypeptides and methods of use thereof. Also provided herein are T-cell receptors (TCRs) that can recognize one or more epitopes of the multiepitopic polypeptides. The therapy provided herein can comprise (i) a TCR, a recombinant nucleic acid encoding the TCR, or cells comprising the TCR or the recombinant nucleic acid encoding the TCR, and (ii) a vaccine composition described herein. The methods and compositions provided herein can be used for the treatment of cancer.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and/or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for cell-based therapies.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
The present disclosure provides T cell receptors (TCRs) that bind to peptide-MHC complexes; isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure provides methods for producing engineered immune cells, engineered immune cell populations, and methods of using the engineered immune cells for treating subjects with cancer and other conditions. The engineered immune cells provided herein can comprise antigen-specific T cells (e.g., neoantigen-specific T cells), TCR-T cells, or CAR-T cells. The engineered immune cells prepared by the methods provided herein can exhibit beneficial phenotypes, such as increased persistence, increased effector function, increased activation function, and/or lower dysfunction.
The present disclosure provides a therapy with vaccine compositions including multiepitopic polypeptides, recombinant nucleic acids encoding multiepitopic polypeptides and methods of use thereof. Also provided herein are T-cell receptors (TCRs) that can recognize one or more epitopes of the multiepitopic polypeptides. The therapy provided herein can comprise (i) a TCR, a recombinant nucleic acid encoding the TCR, or cells comprising the TCR or the recombinant nucleic acid encoding the TCR, and (ii) a vaccine composition described herein. The methods and compositions provided herein can be used for the treatment of cancer.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Kohler, Jessica
Kuksin, Christina M.
Haanen, John B.
Demario, Mark
Abstract
Generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
STICHTING HET NEDERLANDS KANKER INSTITUUT- ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Van Den Burg, Joost Huibert
Kohler, Jessica
Goldstein, Matthew
Fritsch, Ed
De Boer, Renate
Schumacher, Ton
Bakker, Noor
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
BIONTECH US INC. (USA)
Inventor
Friedman, Harvey
Cohen, Gary H.
Awasthi, Sita
Weissman, Drew
Egan, Kevin
Lubinski, John
Güler, Alptekin
Velazquez, Ricardo Sanchez
Uebele, Julia
Vogel, Annette
Pfafenrot, Christina
Ernst, Anna Luise
Hein, Stephanie
Hinz, Sabrina
Dany, Sarah Catharina
Abstract
The present disclosure provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
Compounds disclosed herein have been prepared for use in the treatment of diseases, disorders or conditions treatable by activation of the stimulator of interferon genes (STING) adaptor protein, such as in the treatment or prevention of cancers.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Compounds of formula (IA") disclosed herein have been prepared for use in the treatment of diseases, disorders or conditions treatable by activation of the stimulator of interferon genes (STING) adaptor protein, such as in the treatment or prevention of cancers.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
ex vivo ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Provided herein are compositions relating to tissue-specific antigens, and methods for identifying tissue-specific antigens. Also provided herein are pharmaceutical compositions and methods of treatment that relate to tissue-specific antigens.
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
29.
METHODS AND SYSTEMS FOR PREDICTION OF HLA EPITOPES
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
The present disclosure relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
Compositions and methods for preparing T cell compositions and uses thereof are described, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising at least one of KRAS epitope having a sequence GACGVGKSA that binds to a protein encoded by an HLA allele C03:04; or having a sequence GAVGVGKSA that binds to a protein encoded by an HLA allele C03:03 wherein the respective protein encoded by the HLA allele is expressed in a cell of the subject. Also included are immunogenic compositions comprising peptide(s) comprising an epitope described above, or antigen presenting cells loaded with the peptide(s) comprising the epitope.
Compositions and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
STICHTING HET NEDERLANDS KANKER INSTITUUT ANTONI VAN LEEUWENHOEK ZIEKENHUIS (USA)
BIONTECH US INC. (USA)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Kohler, Jessica
Kuksin, Christina M.
Haanen, John B.
Demario, Mark
Abstract
Generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Kohler, Jessica
Kuksin, Christina M.
Haanen, John B.
Demario, Mark
Abstract
Generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Disclosed herein relates to immunotherapeutic polypeptides comprising neoepitopes, antigen presenting cells comprising the immunotherapeutic polypeptides, and a pharmaceutical composition comprising the immunotherapeutic polypeptides. Also disclosed herein is use of the immunotherapeutic polypeptides in treating a disease or condition.
Provided herein are compositions and methods for preparing T cell compositions and uses thereof, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising an epitope sequence from a library of epitope sequences, wherein each epitope sequence in the library is matched to a protein encoded by an HLA allele and binds to a protein encoded by an HLA allele of the subject, is immunogenic according to an immunogenic assay, is presented by antigen presenting cells according to a mass spectrometry assay, and stimulates T cells to be cytotoxic according to a cytotoxicity assay.
STICHTING HET NEDERLANDS KANKER INSTITUUT ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Kohler, Jessica
Brown, Flavian Duvalle
Kuksin, Christina Murphy
Van Den Berg, Joost Huibert
De Boer, Renate
Bakker, Noor
Schumacher, Ton
Haanen, John
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Provided herein are compositions relating to tissue-specific antigens, and methods for identifying tissue-specific antigens. Also provided herein are pharmaceutical compositions and methods of treatment that relate to tissue-specific antigens.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
46.
METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhis (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Van Den Burg, Joost Huibert
Kohler, Jessica
Goldstein, Matthew
Fritsch, Ed
De Boer, Renate
Schumacher, Ton
Bakker, Noor
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
The present disclosure concerns methods of treating cancer with neoantigenic peptides such that durable clinical benefits are obtained, and compositions and methods for determining whether DCB can be predicted or assessed for a patient to be treated with a therapeutic comprising neoantigen.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
ex vivoex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Compositions and methods for preparing T cell compositions and uses thereof are described, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising at least one of KRAS epitope having a sequence GACGVGKSA (SEQ ID NO: 1) that binds to a protein encoded by an HLA allele C03:04; or having a sequence GAVGVGKSA (SEQ ID NO: 2) that binds to a protein encoded by an HLA allele C03:03 wherein the respective protein encoded by the HLA allele is expressed in a cell of the subject. Also included are immunogenic compositions comprising peptide(s) comprising an epitope described above, or antigen presenting cells loaded with the peptide(s) comprising the epitope.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Compositions and methods for preparing T cell compositions and uses thereof are described, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising at least one of KRAS epitope having a sequence GACGVGKSA that binds to a protein encoded by an HLA allele C03:04; or having a sequence GAVGVGKSA that binds to a protein encoded by an HLA allele C03:03 wherein the respective protein encoded by the HLA allele is expressed in a cell of the subject. Also included are immunogenic compositions comprising peptide(s) comprising an epitope described above, or antigen presenting cells loaded with the peptide(s) comprising the epitope.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
The disclosure herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes. Also disclosed herein are polynucleotides encoding the immunotherapeutic peptides. Also disclosed herein are methods of synthesis of immunotherapeutic peptides comprising neoepitopes and use of the immunotherapeutic compositions including methods of treatment.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
Disclosed herein relates to immunotherapeutic polypeptides comprising neoepitopes, antigen presenting cells comprising the immunotherapeutic polypeptides, and a pharmaceutical composition comprising the immunotherapeutic polypeptides. Also disclosed herein is use of the immunotherapeutic polypeptides in treating a disease or condition.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
Disclosed herein relates to immunotherapeutic polypeptides comprising neoepitopes, antigen presenting cells comprising the immunotherapeutic polypeptides, and a pharmaceutical composition comprising the immunotherapeutic polypeptides. Also disclosed herein is use of the immunotherapeutic polypeptides in treating a disease or condition.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
STICHTING HET NEDERLANDS KANKER INSTITUUT ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Kohler, Jessica
Brown, Flavian Duvalle
Kuksin, Christina Murphy
Van Den Berg, Joost Huibert
De Boer, Renate
Bakker, Noor
Schumacher, Ton
Abstract
ex vivoex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Kohler, Jessica
Brown, Flavian Duvalle
Kuksin, Christina Murphy
Van Den Berg, Joost Huibert
De Boer, Renate
Bakker, Noor
Schumacher, Ton
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
The present disclosure concerns methods of treating cancer with neoantigenic peptides such that durable clinical benefits are obtained, and compositions and methods for determining whether DCB can be predicted or assessed for a patient to be treated with a therapeutic comprising neoantigen.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
Provided herein are compositions and methods for preparing T cell compositions and uses thereof, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising an epitope sequence from a library of epitope sequences, wherein each epitope sequence in the library is matched to a protein encoded by an HLA allele and binds to a protein encoded by an HLA allele of the subject, is immunogenic according to an immunogenic assay, is presented by antigen presenting cells according to a mass spectrometry assay, and stimulates T cells to be cytotoxic according to a cytotoxicity assay.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
65.
COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF
Provided herein are compositions and methods for preparing T cell compositions and uses thereof, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising an epitope sequence from a library of epitope sequences, wherein each epitope sequence in the library is matched to a protein encoded by an HLA allele and binds to a protein encoded by an HLA allele of the subject, is immunogenic according to an immunogenic assay, is presented by antigen presenting cells according to a mass spectrometry assay, and stimulates T cells to be cytotoxic according to a cytotoxicity assay.
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
67.
METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS
The present disclosure provides method for preparing a personalized cancer vaccine. The present disclosure also provides a method to train a machine-learning HLA-peptide presentation prediction model.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/74 - Major histocompatibility complex [MHC]
Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhuis (Netherlands)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Van Den Berg, Joost Huibert
Kohler, Jessica
Goldstein, Matthew
Fritsch, Ed
De Boer, Renate
Schumacher, Ton
Bakker, Noor
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Compositions and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
70.
HLA-based methods and compositions and uses thereof
Systems, compositions, and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The disclosure herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes. Also disclosed herrein are polynucleotides encoding the immunotherapeutic peptides. Also disclosed herein are methods of synthesis of immunotherapeutic peptides comprising neoepitopes and use of the immunotherapeutic compositions including methods of treatment.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals, namely, immunomodulators; anti-cancer
preparations; biological preparations for the treatment of
cancer; pharmaceutical products for the prevention and
treatment of cancer; synthetic peptides for the treatment of
cancer; and vaccine preparations. Conducting early evaluations in the field of new
pharmaceuticals; consulting services in the fields of
biotechnology and pharmaceutical research; pharmaceutical
product development services; pharmaceutical product
evaluation services; pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; research and development of pharmaceuticals for the
treatment of cancer; research and development of vaccines
and medicines; technical research in the field of
pharmaceutical studies; development of platform technology,
namely, cancer immunotherapy platforms for manufacturing
therapeutics; conducting clinical trials for others in the
field of pharmaceuticals for the treatment and prevention of
cancer; and consulting services for others in the field of
design, planning, and implementation of clinical trials. Medical and pharmaceutical consultation; providing
information relating to therapeutic properties of
pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceuticals, namely, immunomodulators; anti-cancer preparations; biological preparations for the medical treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; synthetic peptides for the treatment of cancer; and human vaccine preparations (1) Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of medical biotechnology, pharmaceutical biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, a medical platform for the manufacturing of cancer immunotherapy using bioinformatics, peptide chemistry, and cell biology; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; and consulting services for others in the field of design, planning, and implementation of clinical trials
(2) Medical and pharmaceutical consultation relating to therapeutic properties of pharmaceuticals; Medical and pharmaceutical consultation in the fields of diagnostics and treatment of cancer, immunological and infectious diseases; providing information relating to therapeutic properties of pharmaceuticals
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENH (USA)
BIONTECH US INC. (USA)
Inventor
Van Buuren, Marit M.
Lenkala, Divya Reddy
Van Den Berg, Joost Huibert
Kohler, Jessica
Goldstein, Matthew
Fritsch, Ed
Deboer, Renate
Schumacher, Ton
Bakker, Noor
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of cancer, namely, immunotherapies; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anticancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and human vaccine preparations; medical assays for testing of body fluids (1) Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platform for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer and oncological conditions; and consulting services for others in the field of design, planning, and implementation of clinical trials
(2) Medical and pharmaceutical consultation for providing information relating to therapeutic properties of pharmaceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of cancer, namely, immunotherapies; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anticancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and human vaccine preparations; medical assays for testing of body fluids (1) Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platform for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer and oncological conditions; and consulting services for others in the field of design, planning, and implementation of clinical trials
(2) Medical and pharmaceutical consultation for providing information relating to therapeutic properties of pharmaceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; pharmaceuticals, namely, immunotherapies; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and vaccine preparations; medical assays. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platform for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer and oncological conditions; and consulting services for others in the field of design, planning, and implementation of clinical trials. Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services; medical and pharmaceutical consultation; and providing information relating to therapeutic properties of pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; pharmaceuticals, namely, immunotherapies; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and vaccine preparations; medical assays. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platform for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer and oncological conditions; and consulting services for others in the field of design, planning, and implementation of clinical trials. Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services; medical and pharmaceutical consultation; and providing information relating to therapeutic properties of pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely, immunomodulators; anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; synthetic peptides for the treatment of cancer; and vaccine preparations
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
The present disclosure provides compositions and methods for isolating HLA-peptides from cells. The present disclosure provides a universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of cancer, namely, immunotherapies; oncological preparations; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and vaccine preparations (1) Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of online platform technology, namely, cancer immunotherapy platform for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer and oncological conditions; and consulting services for others in the field of design, planning, and implementation of clinical trials
(2) Medical and pharmaceutical consultancy services for providing information relating to therapeutic properties of pharmaceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceuticals, namely, immunotherapies for the treatment of cancer and oncological conditions; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and vaccine preparations (1) Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; platform technology, namely, a medical platform for the development and manufacturing of cancer immunotherapies using bioinformatics, peptide chemistry, and cell biology; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer and oncological conditions; and consulting services for others in the field of design, planning, and implementation of clinical trials
(2) Consultancy services for medical professionals relating to the use of therapeutic properties of pharmaceuticals for the treatment of cancer and oncological conditions; and providing information relating to therapeutic properties of pharmaceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; synthetic peptides for the treatment of cancer; and cancer vaccine preparations. Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; providing platform technology, namely, cancer immunotherapy platform for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; and consulting services for others in the field of design, planning, and implementation of clinical trials. Medical and pharmaceutical consultation; and providing information relating to therapeutic properties of pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely, immunomodulators; anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; synthetic peptides for the treatment of cancer; and vaccine preparations
